Anti-Cardiolipin IgG Antibodies (aCL IgG)
Autoantibodies targeting cardiolipin in complex with plasma beta-2 glycoprotein I, promoting a hypercoagulable prothrombotic state.
Standard vs. Optimal Reference RangesGPL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<15.0 GPL
General reference distribution across unselected commercial populations.
<10.0 GPL (negative)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds phospholipid-protein complexes on endothelial cells and platelets, upregulating tissue factor and inducing thrombosis.
Differential Diagnosis
Elevated Levels (aCL IgG High)
- •Antiphospholipid Syndrome (APS)
- •Systemic Lupus Erythematosus secondary APS
- •Unexplained recurrent venous/arterial thrombosis
Low Levels (aCL IgG Low)
- •Transient post-viral elevations
- •Normal non-thrombophilic baseline
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for aCL IgG
- Targeted organ system imaging or functional dynamic testing related to antiphospholipid syndrome & thrombosis
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-Cardiolipin IgG Antibodies - The New England Journal of Medicine (2021). PMID: 33990124
- [2]aCL IgG Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Cardiolipin IgG Antibodies (aCL IgG) into overall healthspan optimization.